Katherine Leigh Hull
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katherine Leigh Hull has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- James O. Burton
University of Hospitals of Leicester NHS Trust , Leicester
13 shared publications - Matthew P. M. Graham-Brown
Department of Cardiovascular Sciences, University of Leicester, Leicester LE1 7RH, UK
5 shared publications Alice C Smith
NIHR Biomedical Research Centre , Leicester , UK
3 shared publications- Darren R. Churchward
Department of Infection, Immunity and Inflammation University of Leicester Leicester United Kingdom
3 shared publications - Helen Eborall
Usher Institute, University of Edinburgh, Edinburgh, UK
3 shared publications Alice C. Smith
Leicester Kidney Exercise Team, UoL Academic Unit, Department of Renal Medicine , University Hospitals of Leicester, Leicester General Hospital , Leicester LE5 4PW , UK 2 Department of Infection, Immunity and Inflammation , University of Leicester , Leicester , UK
2 shared publications
Latest Publications
- 9 August 2026
- Published by Wiley in Hemodialysis International
The Impact of Intradialytic Exercise on the Symptom of CKD Associated Pruritus
- 9 August 2026
- Published by Wiley in Hemodialysis International
The Impact of Intradialytic Exercise on the Symptom of CKD Associated Pruritus
- Open Access
- 26 September 2025
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 38 (9) , 2651-2661
Exploring vascular access survival in prevalent thrice-weekly in-centre nocturnal haemodialysis patients
Background: This study explores vascular access complications in patients established on in-centre nocturnal haemodialysis (INHD) compared to conventional haemodialysis. Methods: This was a retrospective cohort study; patients acted as their own control. Data were collected from three centres. Adults established on INHD (intervention) preceded by usual daytime haemodialysis (control) were eligible. Data were collected between 01/01/2009 and 12/31/2021. The data collection period was up to 12 months for both control and intervention periods. The primary outcome was a composite of outcomes related to vascular access complications: hospitalisation, intervention, change in vascular access modality, change in dialysis modality and death. The primary outcome was evaluated by time-to-event rate in days using Kaplan–Meier plots. Statistical significance was accepted at a P < 0.05 . Results: One hundred forty-five individuals were included: median age was 52.0 years (IQR 36.0–65.0), 71.0% ( n = 103) were male, and 57.2% ( n = 83) were White. The primary outcome occurred in 24.1% ( n = 35) during the intervention and in 25.5% ( n = 37) during the control period ( P = 0.875). The 12-month vascular access survival probability was 73.4% (95%CI 65.8–81.0%) for the intervention and 70.6% (95%CI 62.4%-78.8%) for the control period. During the intervention period, arteriovenous grafts were associated with lower vascular access survival ( P < 0.001). Regular vitamin K antagonist was associated with a lower 12-month vascular access survival for both the intervention ( P = 0.044) and the control periods ( P < 0.001). Conclusion: There does not appear to be an increased risk to vascular access events for INHD compared to daytime haemodialysis. Vascular access type and regular anticoagulation were associated with a reduced vascular access survival probability. Graphical
- 26 September 2025
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 38 (9) , 2651-2661
Open AccessExploring vascular access survival in prevalent thrice-weekly in-centre nocturnal haemodialysis patients
Background: This study explores vascular access complications in patients established on in-centre nocturnal haemodialysis (INHD) compared to conventional haemodialysis. Methods: This was a retrospective cohort study; patients acted as their own control. Data were collected from three centres. Adults established on INHD (intervention) preceded by usual daytime haemodialysis (control) were eligible. Data were collected between 01/01/2009 and 12/31/2021. The data collection period was up to 12 months for both control and intervention periods. The primary outcome was a composite of outcomes related to vascular access complications: hospitalisation, intervention, change in vascular access modality, change in dialysis modality and death. The primary outcome was evaluated by time-to-event rate in days using Kaplan–Meier plots. Statistical significance was accepted at a P < 0.05 . Results: One hundred forty-five individuals were included: median age was 52.0 years (IQR 36.0–65.0), 71.0% ( n = 103) were male, and 57.2% ( n = 83) were White. The primary outcome occurred in 24.1% ( n = 35) during the intervention and in 25.5% ( n = 37) during the control period ( P = 0.875). The 12-month vascular access survival probability was 73.4% (95%CI 65.8–81.0%) for the intervention and 70.6% (95%CI 62.4%-78.8%) for the control period. During the intervention period, arteriovenous grafts were associated with lower vascular access survival ( P < 0.001). Regular vitamin K antagonist was associated with a lower 12-month vascular access survival for both the intervention ( P = 0.044) and the control periods ( P < 0.001). Conclusion: There does not appear to be an increased risk to vascular access events for INHD compared to daytime haemodialysis. Vascular access type and regular anticoagulation were associated with a reduced vascular access survival probability. Graphical
- Open Access
- 22 September 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0332389
The effect of a six-month programme of intradialytic cycling on survival and hospitalisations in people requiring haemodialysis: 5-year follow-up of the CYCLE-HD randomised controlled trial
We have previously shown that a six-month programme of intradialytic cycling (IDC) improved cardiovascular structure and function, it is unclear whether these changes are associated with long-term benefits. The aim of this post-trial analysis was to evaluate a programme of IDC on all-cause mortality, hospitalisations and cardiovascular events at five-years. Mortality and hospitalisation data were collected from Hospital Episode Statistics and death certificates. Models were fitted unadjusted and adjusted for age, sex, diabetes, duration of dialysis, and receiving a kidney transplant. Cox proportional hazard models were used for time-to-event analysis to evaluate all-cause mortality. Hospitalisations were analysed using a negative binomial regression model, and length of stay using a generalised linear model. A composite outcome of time to first cardiovascular event, combining cardiovascular mortality and hospitalisations, was evaluated using a Cox model. There was no evidence of a statistically significant effect of treatment allocation on survival (hazard ratio (HR) 1.09, 95% confidence interval (CI): 0.68–1.76, p = 0.71). After adjustment, results remained non-significant (HR 1.22, 95% CI: 0.74–2.01, p = 0.43). There was no evidence of a significant effect on all-cause hospitalisations for unadjusted (p = 0.20) or adjusted (p = 0.25) models. Similar results are reported for cardiovascular hospitalisations (p = 0.30 and p = 0.17). For time to first cardiovascular event there was no evidence of a statistically significant effect (HR 1.39, 95% CI: 0.79–2.72, p = 0.26). The main findings show no evidence that a six-month programme of IDC affected all-cause mortality, hospitalisations, cardiovascular events, or length of stay in hospital at five-years.
- 22 September 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0332389
Open AccessThe effect of a six-month programme of intradialytic cycling on survival and hospitalisations in people requiring haemodialysis: 5-year follow-up of the CYCLE-HD randomised controlled trial
We have previously shown that a six-month programme of intradialytic cycling (IDC) improved cardiovascular structure and function, it is unclear whether these changes are associated with long-term benefits. The aim of this post-trial analysis was to evaluate a programme of IDC on all-cause mortality, hospitalisations and cardiovascular events at five-years. Mortality and hospitalisation data were collected from Hospital Episode Statistics and death certificates. Models were fitted unadjusted and adjusted for age, sex, diabetes, duration of dialysis, and receiving a kidney transplant. Cox proportional hazard models were used for time-to-event analysis to evaluate all-cause mortality. Hospitalisations were analysed using a negative binomial regression model, and length of stay using a generalised linear model. A composite outcome of time to first cardiovascular event, combining cardiovascular mortality and hospitalisations, was evaluated using a Cox model. There was no evidence of a statistically significant effect of treatment allocation on survival (hazard ratio (HR) 1.09, 95% confidence interval (CI): 0.68–1.76, p = 0.71). After adjustment, results remained non-significant (HR 1.22, 95% CI: 0.74–2.01, p = 0.43). There was no evidence of a significant effect on all-cause hospitalisations for unadjusted (p = 0.20) or adjusted (p = 0.25) models. Similar results are reported for cardiovascular hospitalisations (p = 0.30 and p = 0.17). For time to first cardiovascular event there was no evidence of a statistically significant effect (HR 1.39, 95% CI: 0.79–2.72, p = 0.26). The main findings show no evidence that a six-month programme of IDC affected all-cause mortality, hospitalisations, cardiovascular events, or length of stay in hospital at five-years.
- Open Access
UK survey of patient and caregiver perspectives on the impact of chronic kidney disease-associated anaemia
Objective Chronic kidney disease (CKD)-associated anaemia has substantial biopsychosocial impacts. This study explores the impact of CKD-associated anaemia and treatment preferences from the patient perspective. Design Cross-sectional survey. Setting Anonymised online survey implemented by Ipsos UK on behalf of the National Kidney Federation and GSK from October 2022 to January 2023. Participants Data were collected from UK adults living with CKD (self-reported). Primary and secondary outcome measures Outcome measures were exploratory and not predefined. The cross-sectional survey was designed to explore the biopsychosocial impact of living with anaemia on individuals with CKD; their unmet needs; the treatment strategies typically implemented and the associated barriers/facilitators to adherence; the healthcare professional–patient relationship with regard to anaemia diagnosis and management. Results Of 101 participants, 90 (89%) were patients with CKD and 11 (11%) were informal carers. 96 (95%) participants reported symptom(s) relevant to their experience of CKD. 88 (87%) participants reported symptom(s) associated with anaemia and 61 (64%) expressed an impact on daily life including 18 (19%) unable to perform daily activities, 13 (14%) unable to go to work and 9 (9%) reporting poor social life/interactions. 85 (84%) participants reported they have received treatment for anaemia: intravenous iron (n=55, 54%), iron tablets (n=29, 29%), erythropoietin-stimulating agents (ESAs) via an autoinjector (n=28, 28%), ESA injections via a syringe (n=24, 24%), ESA injections via a dialysis machine (n=17, 17%), folic acid (n=22, 22%) and blood transfusion (n=17, 17%). Six of seven (86%) participants who received their ESA from a healthcare professional at home preferred injections whereas 13/27 (48%) participants who injected themselves at home preferred oral tablets. Conclusions There is not a ‘one-size-fits-all’ approach to the management of CKD-associated anaemia. A personalised approach incorporating the treatment preferences of the individual should be explored when discussing treatment options.
Open AccessUK survey of patient and caregiver perspectives on the impact of chronic kidney disease-associated anaemia
Objective Chronic kidney disease (CKD)-associated anaemia has substantial biopsychosocial impacts. This study explores the impact of CKD-associated anaemia and treatment preferences from the patient perspective. Design Cross-sectional survey. Setting Anonymised online survey implemented by Ipsos UK on behalf of the National Kidney Federation and GSK from October 2022 to January 2023. Participants Data were collected from UK adults living with CKD (self-reported). Primary and secondary outcome measures Outcome measures were exploratory and not predefined. The cross-sectional survey was designed to explore the biopsychosocial impact of living with anaemia on individuals with CKD; their unmet needs; the treatment strategies typically implemented and the associated barriers/facilitators to adherence; the healthcare professional–patient relationship with regard to anaemia diagnosis and management. Results Of 101 participants, 90 (89%) were patients with CKD and 11 (11%) were informal carers. 96 (95%) participants reported symptom(s) relevant to their experience of CKD. 88 (87%) participants reported symptom(s) associated with anaemia and 61 (64%) expressed an impact on daily life including 18 (19%) unable to perform daily activities, 13 (14%) unable to go to work and 9 (9%) reporting poor social life/interactions. 85 (84%) participants reported they have received treatment for anaemia: intravenous iron (n=55, 54%), iron tablets (n=29, 29%), erythropoietin-stimulating agents (ESAs) via an autoinjector (n=28, 28%), ESA injections via a syringe (n=24, 24%), ESA injections via a dialysis machine (n=17, 17%), folic acid (n=22, 22%) and blood transfusion (n=17, 17%). Six of seven (86%) participants who received their ESA from a healthcare professional at home preferred injections whereas 13/27 (48%) participants who injected themselves at home preferred oral tablets. Conclusions There is not a ‘one-size-fits-all’ approach to the management of CKD-associated anaemia. A personalised approach incorporating the treatment preferences of the individual should be explored when discussing treatment options.
- Open Access
- 28 June 2024
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 17 (7) , sfae198
Impact of physical activity on surrogate markers of cardiovascular disease in the haemodialysis population
The haemodialysis (HD) population is sedentary, with substantial cardiovascular disease risk. In the general population, small increases in daily step count associate with significant reductions in cardiovascular mortality. This study explores the relationship between daily step count and surrogate markers of cardiovascular disease, including left ventricular ejection fraction (LVEF) and native T1 (a marker of diffuse myocardial fibrosis), within the HD population. This was a post hoc analysis of the association between daily step count and metabolic equivalent of task (MET) and prognostically important cardiac magnetic resonance imaging parameters from the CYCLE-HD study (ISRCTN11299707). Unadjusted linear regression and multiple linear regression adjusted for age, body mass index, dialysis vintage, haemoglobin, hypertension and ultrafiltration volume were performed. Significant relationships were explored with natural cubic spline models with four degrees of freedom (five knots). A total of 107 participants were included [age 56.3 ± 14.1 years, 79 (73.8%) males]. The median daily step count was 2558 (interquartile range 1054–4352). There were significant associations between steps and LVEF (β = 0.292; P = .009) and steps and native T1 (β = −0.245; P = .035). Further modelling demonstrated most of the increase in LVEF occurred at up to 2000 steps/day and there was an inverse dose–response relationship between steps and native T1, with the most pronounced reduction in native T1 between ≈2500 and 6000 steps/day. The results suggest an association between daily step count and parameters of cardiovascular health in the HD population. These findings support the recommendations for encouraging physical activity but are not the justification. Further research should evaluate whether a simple physical activity intervention improves cardiovascular outcomes in individuals receiving maintenance HD.
- 28 June 2024
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 17 (7) , sfae198
Open AccessImpact of physical activity on surrogate markers of cardiovascular disease in the haemodialysis population
The haemodialysis (HD) population is sedentary, with substantial cardiovascular disease risk. In the general population, small increases in daily step count associate with significant reductions in cardiovascular mortality. This study explores the relationship between daily step count and surrogate markers of cardiovascular disease, including left ventricular ejection fraction (LVEF) and native T1 (a marker of diffuse myocardial fibrosis), within the HD population. This was a post hoc analysis of the association between daily step count and metabolic equivalent of task (MET) and prognostically important cardiac magnetic resonance imaging parameters from the CYCLE-HD study (ISRCTN11299707). Unadjusted linear regression and multiple linear regression adjusted for age, body mass index, dialysis vintage, haemoglobin, hypertension and ultrafiltration volume were performed. Significant relationships were explored with natural cubic spline models with four degrees of freedom (five knots). A total of 107 participants were included [age 56.3 ± 14.1 years, 79 (73.8%) males]. The median daily step count was 2558 (interquartile range 1054–4352). There were significant associations between steps and LVEF (β = 0.292; P = .009) and steps and native T1 (β = −0.245; P = .035). Further modelling demonstrated most of the increase in LVEF occurred at up to 2000 steps/day and there was an inverse dose–response relationship between steps and native T1, with the most pronounced reduction in native T1 between ≈2500 and 6000 steps/day. The results suggest an association between daily step count and parameters of cardiovascular health in the HD population. These findings support the recommendations for encouraging physical activity but are not the justification. Further research should evaluate whether a simple physical activity intervention improves cardiovascular outcomes in individuals receiving maintenance HD.
- Open Access
- 2 January 2024
- Published by Taylor & Francis in Health Sociology Review
- Vol. 33 (1) , 24-42
The paradox of haemodialysis: the lived experience of the clocked treatment of chronic illness
Studies exploring the relationship between time and chronic illness have generally focused on measurable aspects of time, also known as linear time. Linear time follows a predictable, sequential order of past, present and future; measured using a clock and predicated on normative assumptions. Sociological concepts addressing lifecourse disruption following diagnosis of chronic illness have served to enhance the understanding of lived experience. To understand the nuanced relationship between time and chronic illness, however, requires further exploration. Here, we show how the implicit assumptions of linear time meet in tension with the lived experience of chronic illness. We draw on interviews and photovoice work with people with end-stage kidney disease in receipt of in-centre-daytime haemodialysis to show how the clocked treatment of chronic illness disrupts experiences of time. Drawing on concepts of 'crip' and 'chronic' time we argue that clocked treatment and the lived experience of chronic illness converge at a paradox whereby clocked treatment allows for the continuation of linear time yet limits freedom. We use the concept of 'crip time' to challenge the normative assumptions implicit within linear concepts of time and argue that the understanding of chronic illness and its treatment would benefit from a 'cripped' starting point.
- 2 January 2024
- Published by Taylor & Francis in Health Sociology Review
- Vol. 33 (1) , 24-42
Open AccessThe paradox of haemodialysis: the lived experience of the clocked treatment of chronic illness
Studies exploring the relationship between time and chronic illness have generally focused on measurable aspects of time, also known as linear time. Linear time follows a predictable, sequential order of past, present and future; measured using a clock and predicated on normative assumptions. Sociological concepts addressing lifecourse disruption following diagnosis of chronic illness have served to enhance the understanding of lived experience. To understand the nuanced relationship between time and chronic illness, however, requires further exploration. Here, we show how the implicit assumptions of linear time meet in tension with the lived experience of chronic illness. We draw on interviews and photovoice work with people with end-stage kidney disease in receipt of in-centre-daytime haemodialysis to show how the clocked treatment of chronic illness disrupts experiences of time. Drawing on concepts of 'crip' and 'chronic' time we argue that clocked treatment and the lived experience of chronic illness converge at a paradox whereby clocked treatment allows for the continuation of linear time yet limits freedom. We use the concept of 'crip time' to challenge the normative assumptions implicit within linear concepts of time and argue that the understanding of chronic illness and its treatment would benefit from a 'cripped' starting point.
- Open Access
- 12 August 2023
- Published by Springer Nature in Trials
- Vol. 24 (1) , 1-14
The NightLife study — the clinical and cost-effectiveness of thrice-weekly, extended, in-centre nocturnal haemodialysis versus daytime haemodialysis using a mixed methods approach: study protocol for a randomised controlled trial
Background: In-centre nocturnal haemodialysis (INHD) offers extended-hours haemodialysis, 6 to 8 h thrice-weekly overnight, with the support of dialysis specialist nurses. There is increasing observational data demonstrating potential benefits of INHD on health-related quality of life (HRQoL). There is a lack of randomised controlled trial (RCT) data to confirm these benefits and assess safety. Methods: The NightLife study is a pragmatic, two-arm, multicentre RCT comparing the impact of 6 months INHD to conventional haemodialysis (thrice-weekly daytime in-centre haemodialysis, 3.5–5 h per session). The primary outcome is the total score from the Kidney Disease Quality of Life tool at 6 months. Secondary outcomes include sleep and cognitive function, measures of safety, adherence to dialysis and impact on clinical parameters. There is an embedded Process Evaluation to assess implementation, health economic modelling and a QuinteT Recruitment Intervention to understand factors that influence recruitment and retention. Adults (≥ 18 years old) who have been established on haemodialysis for > 3 months are eligible to participate. Discussion: There are 68,000 adults in the UK that need kidney replacement therapy (KRT), with in-centre haemodialysis the treatment modality for over a third of cases. HRQoL is an independent predictor of hospitalisation and mortality in individuals on maintenance dialysis. Haemodialysis is associated with poor HRQoL in comparison to the general population. INHD has the potential to improve HRQoL. Vigorous RCT evidence of effectiveness is lacking. The NightLife study is an essential step in the understanding of dialysis therapies and will guide patient-centred decisions regarding KRT in the future. Trial registration: Trial registration number: ISRCTN87042063. Registered: 14/07/2020.
- 12 August 2023
- Published by Springer Nature in Trials
- Vol. 24 (1) , 1-14
Open AccessThe NightLife study — the clinical and cost-effectiveness of thrice-weekly, extended, in-centre nocturnal haemodialysis versus daytime haemodialysis using a mixed methods approach: study protocol for a randomised controlled trial
Background: In-centre nocturnal haemodialysis (INHD) offers extended-hours haemodialysis, 6 to 8 h thrice-weekly overnight, with the support of dialysis specialist nurses. There is increasing observational data demonstrating potential benefits of INHD on health-related quality of life (HRQoL). There is a lack of randomised controlled trial (RCT) data to confirm these benefits and assess safety. Methods: The NightLife study is a pragmatic, two-arm, multicentre RCT comparing the impact of 6 months INHD to conventional haemodialysis (thrice-weekly daytime in-centre haemodialysis, 3.5–5 h per session). The primary outcome is the total score from the Kidney Disease Quality of Life tool at 6 months. Secondary outcomes include sleep and cognitive function, measures of safety, adherence to dialysis and impact on clinical parameters. There is an embedded Process Evaluation to assess implementation, health economic modelling and a QuinteT Recruitment Intervention to understand factors that influence recruitment and retention. Adults (≥ 18 years old) who have been established on haemodialysis for > 3 months are eligible to participate. Discussion: There are 68,000 adults in the UK that need kidney replacement therapy (KRT), with in-centre haemodialysis the treatment modality for over a third of cases. HRQoL is an independent predictor of hospitalisation and mortality in individuals on maintenance dialysis. Haemodialysis is associated with poor HRQoL in comparison to the general population. INHD has the potential to improve HRQoL. Vigorous RCT evidence of effectiveness is lacking. The NightLife study is an essential step in the understanding of dialysis therapies and will guide patient-centred decisions regarding KRT in the future. Trial registration: Trial registration number: ISRCTN87042063. Registered: 14/07/2020.
- 7 August 2023
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 32 (6) , 537-543
Does cooled dialysate still have a role in reducing intradialytic stress? Implications of the MyTEMP trial
Purpose of review: There is an excess of cardiovascular morbidity and mortality in the maintenance haemodialysis population. Targeting traditional risk factors (e.g. hypercholesterolaemia) do not improve cardiovascular outcomes. Repeated myocardial stunning during haemodialysis is an important nontraditional risk, resulting in pathological cardiac remodelling and fibrosis. This review explores dialysate cooling as a management strategy to promote haemodynamic stability, reduce myocardial injury, and improve cardiovascular disease outcomes for individuals receiving maintenance haemodialysis. Recent findings: Observational data and small interventional studies demonstrate dialysate cooling has the potential to reduce end-organ damage and provide cardioprotection, renal protection and neuroprotection compared with standard care. These data are limited by the small sample sizes, short follow-up times and lack of long-term patient important outcomes. The MyTEMP study, a multicentre pragmatic randomized controlled trial, demonstrated cooled dialysate (0.5°C below body temperature) vs. standard care did not improve cardiovascular outcomes for prevalent haemodialysis patients. Summary: Dialysate cooling has been widely adopted into routine clinical practice; the MyTEMP study challenges the unit-level approach to implementing dialysate cooling. Due to methodological limitations, the absence of other important patient outcome measures, and lack of granularity of patient-level data, dialysate cooling should not be hastily removed from all dialysis care and warrants further research.
- 7 August 2023
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 32 (6) , 537-543
Does cooled dialysate still have a role in reducing intradialytic stress? Implications of the MyTEMP trial
Purpose of review: There is an excess of cardiovascular morbidity and mortality in the maintenance haemodialysis population. Targeting traditional risk factors (e.g. hypercholesterolaemia) do not improve cardiovascular outcomes. Repeated myocardial stunning during haemodialysis is an important nontraditional risk, resulting in pathological cardiac remodelling and fibrosis. This review explores dialysate cooling as a management strategy to promote haemodynamic stability, reduce myocardial injury, and improve cardiovascular disease outcomes for individuals receiving maintenance haemodialysis. Recent findings: Observational data and small interventional studies demonstrate dialysate cooling has the potential to reduce end-organ damage and provide cardioprotection, renal protection and neuroprotection compared with standard care. These data are limited by the small sample sizes, short follow-up times and lack of long-term patient important outcomes. The MyTEMP study, a multicentre pragmatic randomized controlled trial, demonstrated cooled dialysate (0.5°C below body temperature) vs. standard care did not improve cardiovascular outcomes for prevalent haemodialysis patients. Summary: Dialysate cooling has been widely adopted into routine clinical practice; the MyTEMP study challenges the unit-level approach to implementing dialysate cooling. Due to methodological limitations, the absence of other important patient outcome measures, and lack of granularity of patient-level data, dialysate cooling should not be hastily removed from all dialysis care and warrants further research.
- Open Access
- 16 June 2021
- Published by Wiley in Hemodialysis International
- Vol. 25 (4) , 447-456
Evaluating the clinical experience of a regional in‐center nocturnal hemodialysis program: The patient and staff perspective
Introduction End-stage kidney disease causes significant morbidity, mortality, and reduced quality of life. Despite improvements in conventional hemodialysis, these problems persist. In-center nocturnal hemodialysis (INHD) has been shown to be beneficial in observational studies. This report outlines a 4-year renal network experience of INHD from the patient and frontline staff perspective. Methods Staff and patients' experiences of INHD were evaluated through two work streams. Work stream one: 12 patients who chose to stop INHD and 24 patients who chose to continue with INHD completed an anonymous survey. Work stream two: one-to-one interviews with 20 patients receiving INHD and seven staff working INHD shifts were conducted. Clinical incident reporting for conventional hemodialysis and INHD from April 2014 to December 2018 was reviewed. Findings Work stream one: Five themes were identified; facilities, time, health and well-being, sleep, and transport. A patient “starter pack” was developed and improvements to the dialysis unit were completed. Work stream two: Patient interviews demonstrated starter packs to aid sleep were well received; sleep itself was not a single reason to discontinue INHD. Staff indicated that their greatest concern was staffing levels; although staff-to-patient ratio remains unchanged, total numbers on INHD shifts were fewer, causing concern around less colleague availability for support during an emergency. Safety: 363 clinical incidents were reported across all dialysis shifts; for conventional hemodialysis, a larger proportion were due to medical interventions, infection control, and transport; for INHD, most incidents centered around communication with patients and relatives, delays in patient transfer, and issues with medical equipment or facilities. Discussion Patients continue with INHD due to increased social time and perceived health benefits. Patient starter packs and adjustments to the dialysis unit may enhance sleep. This experience has optimized the design of the NightLife study; a randomized controlled trial evaluated the effect of INHD on quality of life.
- 16 June 2021
- Published by Wiley in Hemodialysis International
- Vol. 25 (4) , 447-456
Open AccessEvaluating the clinical experience of a regional in‐center nocturnal hemodialysis program: The patient and staff perspective
Introduction End-stage kidney disease causes significant morbidity, mortality, and reduced quality of life. Despite improvements in conventional hemodialysis, these problems persist. In-center nocturnal hemodialysis (INHD) has been shown to be beneficial in observational studies. This report outlines a 4-year renal network experience of INHD from the patient and frontline staff perspective. Methods Staff and patients' experiences of INHD were evaluated through two work streams. Work stream one: 12 patients who chose to stop INHD and 24 patients who chose to continue with INHD completed an anonymous survey. Work stream two: one-to-one interviews with 20 patients receiving INHD and seven staff working INHD shifts were conducted. Clinical incident reporting for conventional hemodialysis and INHD from April 2014 to December 2018 was reviewed. Findings Work stream one: Five themes were identified; facilities, time, health and well-being, sleep, and transport. A patient “starter pack” was developed and improvements to the dialysis unit were completed. Work stream two: Patient interviews demonstrated starter packs to aid sleep were well received; sleep itself was not a single reason to discontinue INHD. Staff indicated that their greatest concern was staffing levels; although staff-to-patient ratio remains unchanged, total numbers on INHD shifts were fewer, causing concern around less colleague availability for support during an emergency. Safety: 363 clinical incidents were reported across all dialysis shifts; for conventional hemodialysis, a larger proportion were due to medical interventions, infection control, and transport; for INHD, most incidents centered around communication with patients and relatives, delays in patient transfer, and issues with medical equipment or facilities. Discussion Patients continue with INHD due to increased social time and perceived health benefits. Patient starter packs and adjustments to the dialysis unit may enhance sleep. This experience has optimized the design of the NightLife study; a randomized controlled trial evaluated the effect of INHD on quality of life.
- 2 March 2021
- Published by BMJ in BMJ Case Reports
- Vol. 14 (3) , e240579
Resolution of warfarin-induced alopecia with conversion to apixaban
Warfarin is frequently prescribed as a long-term anticoagulant in patients with end-stage kidney disease as direct oral anticoagulants undergo renal excretion. Anticoagulation is a rare cause of alopecia in adults and is thought to be due to the promotion of the ‘resting phase’ of hair follicles. In this case report, a prevalent haemodialysis female patient required long-term anticoagulation following a complex pulmonary embolus and dialysis access complications. After commencing warfarin therapy, the patient reported generalised loss and thinning of her hair. All other potential causes were excluded. Cessation of warfarin therapy and conversion to apixaban with close monitoring alleviated the hair loss. Warfarin therapy is a rare cause of alopecia but should be considered in patients on long-term anticoagulation when other diagnoses have been excluded. Hair loss has a profoundly negative impact on patient quality of life and should prompt investigation to determine the underlying cause.
- 2 March 2021
- Published by BMJ in BMJ Case Reports
- Vol. 14 (3) , e240579
Resolution of warfarin-induced alopecia with conversion to apixaban
Warfarin is frequently prescribed as a long-term anticoagulant in patients with end-stage kidney disease as direct oral anticoagulants undergo renal excretion. Anticoagulation is a rare cause of alopecia in adults and is thought to be due to the promotion of the ‘resting phase’ of hair follicles. In this case report, a prevalent haemodialysis female patient required long-term anticoagulation following a complex pulmonary embolus and dialysis access complications. After commencing warfarin therapy, the patient reported generalised loss and thinning of her hair. All other potential causes were excluded. Cessation of warfarin therapy and conversion to apixaban with close monitoring alleviated the hair loss. Warfarin therapy is a rare cause of alopecia but should be considered in patients on long-term anticoagulation when other diagnoses have been excluded. Hair loss has a profoundly negative impact on patient quality of life and should prompt investigation to determine the underlying cause.